Kriya Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Kriya Therapeutics, Inc. holds 24 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 22 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 2 trademarks are registered and 11 are pending. Notable registered marks include SIRVE and KRIYA THERAPEUTICS. The owner is based in Palo Alto, CA.
3790 El Camino Real, Unit #614
Palo Alto, CA 94306
Showing of trademarks Trademarks
Trademark Classifications
Kriya Therapeutics, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Kriya Therapeutics, Inc. have?
Kriya Therapeutics, Inc. has 24 U.S. trademarks filed with the USPTO. Of these, 2 registered, 11 pending, 11 abandoned.
What trademark classes does Kriya Therapeutics, Inc. file in?
Kriya Therapeutics, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Kriya Therapeutics, Inc.'s most well-known trademarks?
Kriya Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as SIRVE and KRIYA THERAPEUTICS. These are among 2 currently registered trademarks in the portfolio.
What is Kriya Therapeutics, Inc.'s trademark registration success rate?
Kriya Therapeutics, Inc. has a 15% trademark registration rate, with 2 out of 13 resolved applications resulting in successful registration. Currently, 11 applications are pending review.